Prof Schwartz discusses the use of targeted therapy to treat sarcomas. Imatinib has been shown to reduce recurrence rates and has traditionally been administered daily for a year after surgery. Prof Schwartz speaks about wok that has been done that will help clinicians decide which patients need this treatment and which do not. Some less encouraging results include research investigating the use of IGF-1R inhibitors. Despite initially positive results, this trial has now been shown to be relatively unsuccessful, however, trials are currently underway to find out if this can be overcome by combining IGF-1R inhibitors with rapamycin, a drug that blocks the TOR pathway. Prof Schwartz talks about the results of a phase II trial into palifosfamide, a cytotoxic that has similar effects to ifosfamide but without many of the associated side effects.